MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.
Afrezza received U.S. Food and Drug Administration (FDA) approval in 2014 and is marketed directly by MannKind in the United States. The company initially entered into a co-promotion agreement with Sanofi for U.S. distribution of Afrezza, though that partnership concluded in 2016, prompting MannKind to establish its own commercial infrastructure. Beyond Afrezza, MannKind continues to evaluate additional indications for its Technosphere platform, including therapies for pulmonary hypertension and other conditions where rapid drug uptake via inhalation may offer clinical benefits.
Founded in 1991 by biomedical entrepreneur Dr. Alfred E. Mann, MannKind is headquartered in Westlake Village, California. Its leadership team includes President and Chief Executive Officer Michael Castagna, who has guided the company’s commercial operations and pipeline development since 2015. MannKind’s research and development activities are conducted primarily in the United States, with plans to seek regulatory approvals and partnerships in international markets as part of its long‐term growth strategy.
Through its focus on inhalation science and patient‐centric product design, MannKind aims to broaden the applications of its Technosphere technology beyond diabetes care. The company remains committed to advancing novel therapies that leverage the lung as a route of drug delivery, potentially transforming treatment paradigms for metabolic and respiratory diseases.
AI Generated. May Contain Errors.
